GLP-1s for OSA
Tirzepatide became the first medication FDA-approved for moderate-to-severe OSA in adults with obesity (December 2024), based on the SURMOUNT-OSA trials.
What SURMOUNT-OSA showed
In two pivotal trials (one with concurrent CPAP, one without), tirzepatide reduced the apnea–hypopnea index (AHI) by 27–30 events per hour relative to placebo over 52 weeks in adults with moderate-to-severe OSA and obesity. Roughly 40–50% of treated patients achieved an AHI of fewer than 5 events per hour — essentially a remission threshold.
Mechanism
The benefit is thought to be primarily mediated through weight loss reducing upper-airway fat deposition and improving compliance of the pharyngeal airway — though a direct effect on respiratory drive cannot be excluded.
Clinical role
Tirzepatide does not replace CPAP for all patients but offers a pharmacologic option for those intolerant of positive-airway-pressure therapy or seeking an adjunct. Coverage and prior-authorization pathways for this indication remain in flux.